Ras and a-factor-converting enzyme 1 (Rce1) is located in the endoplasmic reticulum (ER) and is thought to be responsible for endoproteolytic processing of the vast majority of CAAX proteins. Endoplasmic reticulum stress (ERS) plays an important role in renal cell carcinoma (RCC); however, the expression and role of Rce1 in RCC have not been extensively studied. We aimed to investigate the expression of Rce1 in RCC tissues and its molecular mechanism in ERS-induced apoptosis in RCC 786-O cells. We first used western blotting, quantitative reverse transcriptasepolymerase chain reaction, and immunohistochemistry to detect the Rce1 expression in renal carcinoma tissues and paracancerous tissues. It was found that Rce1 expression was upregulated in RCC tissues, and its positive expression level was strongly associated with clinicopathologic features. Next, we detected the expression of Rce1 in human embryonic kidney cell line HEK293 and human renal carcinoma cell lines 786-O, ACHN, and A498. Higher expression of Rce1 was found in human renal carcinoma cell lines, especially in 786-O cells. Knockdown of Rce1 in 786-O cells increased apoptosis and inhibited proliferation (P < 0.05). Moreover, downregulation of Rce1 upregulated the expression of the pro-apoptotic protein Bax, but downregulated the expression of the anti-apoptotic protein Bcl-2. Further studies showed that downregulation of Rce1 also affected the expression of ERS factors. In conclusion, our results indicated that Rce1 plays a key role in RCC. Low expression of Rce1 might indirectly increase apoptosis and inhibit proliferation of renal carcinoma cells through ERS.
Introduction
Renal cell carcinoma (RCC) is considered to be one of the most common malignancies of the urinary system [1] . The typical triad of renal carcinoma (abdominal pain, hematuria, and lump) is present in only~10% of patients [2] . Advanced RCC has been associated with a poor prognosis, with a 5-year survival rate of 5%-10% [3] . Therefore, it is important to explore new biomarkers for early diagnosis, targeted therapy, and prognostic determination of RCC [4] .
Ras and a-factor-converting enzyme 1 (Rce1) is a Type II CAAX protein endopeptidase, which is located on the endoplasmic reticulum (ER) membrane. It is the only known member of a new family of glutamate intramembrane proteases, which can hydrolyze three amino acids at CAAX protein termini by facilitating subsequent methylation modification [5, 6] . Rce1 has been found to be active in human carcinoma [7] . A recent study showed that Rce1 inhibitor has potential therapeutic activity in human colon carcinoma cells [8] . Moreover, studies also showed that the absence of Rce1 leads to some malignant diseases including cardiomyopathy [9] [10] [11] . Therefore, insights into the mechanisms of Rce1 might be of great relevance to the occurrence and development of tumors.
Endoplasmic reticulum stress (ERS) is induced by any dysfunction in normal ER process [12] . When ERS occurs, the unfolded protein response is first activated as a protective mechanism to remove misfolded proteins in the ER [13] . ERS activates protein kinase-like endoplasmic reticulum kinase (PERK), which upregulates the phosphorylation of eukaryotic translation initiation factor-2α (eIF2α), thereby activating transcription factor 4 (ATF4) and CCAAT enhancer-binding protein homologous protein (CHOP) sequentially [14, 15] . Activation of the PERK-eIF2α-ATF4 signaling pathway regulates the cell apoptosis mediated by the Bcl-2 protein family [16] [17] [18] . Thus, the ERS plays a critical role in cellular apoptosis, which is associated with several diseases including cancers [19, 20] .
In this study, we first explored the differential expression of Rce1 in renal tissues and also investigated its regulatory effect on 786-O cell apoptosis and proliferation through the ERS PERK-eIF2α-ATF4 signaling pathway. Our studies not only open new avenues for future research on Rce1, but also provide new ideas for the molecular diagnosis, molecular typing, and precise treatment of RCC.
Materials and Methods

Specimens
From December 2012 to October 2015, a total of 82 RCC and 35 paracancerous tissues were collected from patients undergoing radical/partial nephrectomy in the Urology Department of the First Affiliated Hospital of Chongqing Medical University. All specimens were diagnosed by postoperative pathology and were derived from newly formed cancerous tissues with their complete clinical data. The patients did not receive preoperative chemoradiotherapy. The patients' authorized agreements were acquired for all the process of dealing with their tissues, and the study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University.
Cell culture
Human embryonic kidney cell line HEK293, human renal carcinoma cell lines 786-O, ACHN, and A498 were purchased from the American Type Culture Collection (Manassas, USA). Cells were routinely cultured in RPMI 1640 medium (Hyclone Technologies, Logan, USA) containing 10% fetal bovine serum (Hyclone) and 100 U/ml anti-bis (Life Technologies, Carlsbad, USA) in a 37°C, 5% CO 2 humidified incubator.
Cell grouping
Three short hairpin RNA (shRNA) sequences ( Table 1 ) specific for human Rce1 (GI:NM_005133) and one negative control sequence were constructed and confirmed. Lentivirus was provided and titered by Invitrogen Corporation (Carlsbad, USA). Cells of the shRce1 group were transfected using shRce1 lentivirus with a multiplicity of infection of 10. The negative control group was transfected using rLV-hScramble sequences and the blank control group was not treated. After 48 h following lentivirus transfection, cells were observed under an inverted fluorescence microscope (TE2000U; Nikon, Tokyo, Japan) to determine the transfection rate of each group (transfection rate = number of cells under fluorescence vision/number of cells under normal light vision × 100%). The lentivirus that most significantly downregulated Rce1 (shRce1-1) was used for further studies.
Apoptosis analysis by flow cytometry
Cells of each group were seeded in a six-well plate at a density of 1 × 10 6 cells/ml. After trypsin digestion and centrifugation, cells were gently blown and rinsed twice with phosphate buffered saline to give a single-cell suspension. Cells were dually stained using Annexin V-FITC (Nanjing KeyGen Biotech Co., Ltd, Nanjing, China) and 7-amino-actinomycin D (BD Pharmingen, San Jose, USA), and incubated at 4°C in the dark for 15 min. The rate of apoptosis in each group was examined using a flow cytometer (Becton Dickinson, Madison, USA). All experiments were performed in triplicate and independently repeated three times.
Cell proliferation detection
Cells of each group were seeded in a 96-well plate at a density of 2000 cells/well and 10 μl CCK-8 solution (Dojindo, Kumamoto, Japan) was added to each well every 24 h. After incubation at 37°C for 2 h, the absorbance value at 450 nm was detected using a Microplate Reader (Bio-Rad, Hercules, USA). Three duplicate wells were used for all specimens in each test.
Immunohistochemistry assay
Immunohistochemistry assay was conducted according to the instructions provided in the immunohistochemistry kit (Zhongshan Golden Bridge Bio-technology, Beijing, China). Briefly, 5-μm paraffin sections were dewaxed with dimethylbenzene and hydrated through an ethanol gradient, followed by antigen recovery with citrate buffer and inhibition of catalase with 3% hydrogen peroxide. Paraffin sections were incubated with rabbit anti-human Rce1 antibody (1:100, SC-133951; Santa Cruz Biotechnology, Santa Cruz, USA) overnight at 4°C. The sections were reacted with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG) (Beyotime, Haimen, China) at 37°C for 20 min, followed by staining with diaminobenzidine and counterstaining with hematoxylin (Beyotime), and finally mounted with neutral resin. Images were acquired using an Olympus BX51 microscopic/DP71 Digital Camera System (Ina-shi, Nagano, Japan). The score of each section was determined according to staining percentage and intensity using the following method. Mean percentage of stained cells in five fields under high magnification (×100) was scored as follows: 0 (no stained cells), 1 (1%-25%), 2 (26%-50%), 3 (51%-75%), and 4 (76%-100%). Staining intensity was determined by the presence of brownish yellow or deep yellow granules in cytoplasm as follows: 0 (no staining), 1 (pale brownish yellow), 2 (brownish yellow), and 3 (tan). The final score was obtained by multiplication of the above two scores: 0 referred to negative (−), 1-3 referred to weakly positive (+), 4-6 referred to positive (++), and 8-12 referred to strongly positive (+++) staining. For further analyzes, samples were divided into two groups: negative and weakly positive (0-3 points) or moderately and strongly positive (4-12 points). The immunostaining scores, Fuhrman grading, and T staging of the patients were assessed in a double-blind manner by two senior pathologists [21] [22] [23] .
Western blot analysis
Total protein was extracted from tissues or cells using lytic buffer containing protease inhibitor (Sigma, St Louis, USA). The protein concentrations were determined according to the instructions provided in the BCA Protein Assay Kit (Beyotime). Samples containing 100 μg of protein were separated by electrophoresis in a 10% separation gel and transferred to 0.45-μm polyvinylidene fluoride membrane (Millipore Massachusetts, Billerica, USA). Membranes were blocked with 5% non-fat milk and then incubated overnight at 4°C with antibody dilutions, followed by incubation at room temperature with HRP-conjugated goat anti-rabbit or anti-mouse IgG (1:3000; Zhongshan Golden Bridge Bio-technology). Signal was detected by chemiluminescence in GelDoc XR+ imager (BioRad) using an ECL kit (Advansta, Menlo Park, USA), and the images were analyzed using Quantity One software. Primary antibodies against the following proteins were used: rabbit anti-human Rce1 antibody (1:1000), ATF4 (1:500; Sangon Biotech, Shanghai, China), CHOP (1:500; Sangon Biotech), as well as PERK, p-PERK, ATF6, cleaved-ATF6, XBP1, GRP78, eIF2α, p-eIF2α, BCL-2, and BAX (1:2000; ImmunoWay, Plano, USA). Anti-β-actin antibody (1:3000; Santa Cruz Biotechnology) was used as the internal reference.
qRT-PCR
Total ribonucleicacid (RNA) was extracted using RNAiso Plus reagent (Takara, Dalian, China) and transcribed into complementary DNA using a reverse transcription kit. PCR was performed in a total volume of 10 μl with SYBR Green PCR mix (Takara) as the fluorescent dye using the CFX Manager Real-time PCR system (Bio-Rad). GAPDH was used as the internal reference. The reaction conditions were pre-heating at 95°C for 3 min, followed by 40 cycles of denaturation at 95°C for 30 s and annealing at 60°C for 30 s. Gene expression was represented as ΔCt = Ct gene −Ct reference , and the multiplication ratio was obtained using the 2 −ΔCt method.
The primers used were as follows: Rce1 upstream sequence, 5′-CTCTGGAGGGAACTCACAGG-3′ and downstream sequence, 5′-GAATCATGGTCAGCAACAGG-3′; GAPDH upstream sequence, 5′-ATAGCACAGCCTGGATAGCAACGTAC-3′ and downstream sequence, 5′-CACCTTCTACAATGAGCTGCGTGTG-3′.
Statistical analysis
Statistical analyses were performed using SPSS 19.0 software. All experimental data were expressed as the mean ± SD. Relationships between Rce1 expression and clinical characteristics of cases were analyzed using chi-square or Fisher's exact test. Comparisons of different groups were conducted using independent sample t-test or the ANOVA method for multiple specimens. P < 0.05 was considered of statistically significant difference.
Results
The expression of Rce1 was increased in RCC and associated with clinicopathologic features
To investigate the differential expression of Rce1 between RCC tissues and paracancerous tissues, quantitative reverse transcriptasepolymerase chain reaction (qRT-PCR) and western blot analysis were performed. The results revealed that Rce1 expression was upregulated in the 12 renal carcinoma tissues compared with paired paracancerous tissues ( Fig. 1 and Table 2 ). The same results were obtained by immunohistochemistry ( Fig. 2 and Table 3 ). Among the 82 renal carcinoma tissues, negative/weakly positive staining was observed in 24 cases, whereas moderately/strongly positive staining was observed in 58 cases. We also analyzed the relationship between Rce1 expression and clinicopathologic characteristics of renal carcinoma. The expression level of Rce1 was associated with Fuhrman grading (P = 0.003), T staging (P = 0.029), and distant metastasis (P = 0.029), but showed no relationship with age (P = 0.912) and gender (P = 0.905) ( Table 4) . These results demonstrated that Rce1 was usually overexpressed in RCC, suggesting that it might be considered as an oncogene.
The effect of Rce1 knockdown on apoptosis of 786-O cells
In order to further investigate the biological function of Rce1, qRT-PCR, and western blot were adopted to explore the expression of Rce1 in renal cell lines. The results demonstrated that the expression of Rce1 in renal carcinoma cell lines 786-O, ACHN, and A498 was higher than that in HEK293 cells (Fig. 3A) . At 48 h after transfection of 786-O cells with shRNA specific for Rce1, the cellular infection rate was greater than 95% (Fig. 3B) , and Rce1 expression level was significantly downregulated compared with cells transfected with Scramble-shRNA (Negative control) and the blank control group (Fig. 3C) . The lentivirus that most significantly downregulated Rce1 (shRce1-1) was used for further study. Flow cytometry results showed an increased apoptosis rate in cells transfected with shRce1-1 ( Fig. 4A , P < 0.05). Moreover, CCK-8 results demonstrated a significantly reduced absorbance value of the shRce1-1 group (Fig. 4B , P < 0.05) compared with the control groups. Additionally, knockdown of Rce1 with shRce1-1 downregulated Bcl-2 expression but upregulated Bax expression (Fig. 4C) . These results indicated that low Rce1 expression could enhance apoptosis, but suppress the proliferation of renal carcinoma cells.
Downregulation of Rce1 activated PERK-eIF2α-ATF4 signaling pathway through ERS
Since Rce1 is a resident protease on the ER, we speculated that its mechanism to regulate apoptosis of tumor cells may be associated with ERS. So we further investigated the expression of ERS-related proteins by western blotting and found that the expressions of PERK, p-PERK, ATF6, cleaved-ATF6, and XBP-1 were upregulated but that of GRP78 was downregulated after Rce1 knockdown (Fig. 4C) . Thus, our study demonstrated that factors involved in PERK-eIF2α-ATF4 signaling, which play a key role in the ERS, were significantly upregulated in the shRce1-1 group. In addition, after treatment with the ERS inhibitor 4-phenylbutyric acid (4-PBA; Sigma), the expression of PERKeIF2α-ATF4 signaling factors was downregulated in the shRce1-1 group. Moreover, the expression of Bax was downregulated whereas that of Bcl-2 was upregulated in the 4-PBA-treated shRce1-1 group, while no significant change was observed in the negative control group (Fig. 5) . These results confirmed that the regulatory effect of Rce1 on 786-O cell apoptosis might be associated with ERS, especially the PERK-eIF2α-ATF4 signaling pathway. 
Discussion
Many novel biomarkers have been shown to be beneficial in clinical diagnosis, staging, classification, and prognosis of RCC [24] . However, due to unsatisfactory diagnostic and treatment outcomes, there is still an urgent need for tumor markers with high specificity and high sensitivity for diagnosis and prediction of prognosis for renal carcinoma. Huang et al. [7] showed that Rce1 expression was increased during the development of prostate cancer, consistent with our finding that Rce1 expression was upregulated in renal carcinoma tissues and associated with clinicopathologic features. We also found that low Rce1 expression could suppress the proliferation of 786-O cells and enhance apoptosis, which was related to changes in expression of the pro-apoptotic protein Bax and anti-apoptotic protein Bcl-2. Although previous studies have revealed that Rce1 is involved in processing amino acids in CAAX proteins [6, 25] , the mechanism of Rce1 in cancer remains unclear. We found that ER stress was induced after Rce1 knockdown and PERK-eIF2α-ATF4 signaling factors were extensively expressed in the shRce1-1 group. Furthermore, treatment with the ERS inhibitor 4-PBA [26] after Rce1 knockdown downregulated the expression of PERK-eIF2α-ATF4 signaling factors. Moreover, expression of Bax expression was downregulated and that of Bcl-2 was upregulated. These results confirmed that Rce1 regulates the apoptosis associated with ERS, in particular through the PERK-eIF2α-ATF4 signaling pathway.
There are several explanations for our findings. First, since Rce1 is a resident protease on the ER and we found that Rce1 could regulate PERK-eIF2α-ATF4 signaling thought ERS, we infer that the effect of Rce1 on RCC may be related to ERS. Second, studies have revealed that persistent ERS is likely to trigger cell apoptosis [27] and, moreover, that PERK signaling is involved in the regulation of apoptosis caused by ER stress [28] [29] [30] [31] . We also showed that Rce1 could regulate apoptosis though Bax and Bcl-2. We therefore propose that the regulatory mechanism of Rce1 in the induction of apoptosis of tumor cells may be associated with ERS.
It should be noted that there are still several limitations in this study. First, we strictly selected participants to control potential heterogeneity, which led to a small number of cases (82 patients). Further analysis with a larger sample size is needed to further confirm our results. Second, the relationship between Rce1 expression and cancer-specific death of RCC patients should be examined. Third, research on the cellular functions and molecular mechanisms of Rce1 was not comprehensive, and further studies are necessary to verify the role of Rce1 in the development and progression of RCC. In summary, this study confirmed that Rce1, functioning as an oncogene, plays an important role in the occurrence and development of RCC. Rce1 also inhibits apoptosis of renal carcinoma cells. Its mechanism in regulating apoptosis might be associated with persistent activation of the PERK-eIF2α-ATF4 signaling pathway under conditions of ERS. Furthermore, Rce1 might be a target for therapy of RCC. However, basic and clinical research on the role of Rce1 is still at an initial stage, and its molecular mechanism in the occurrence and development of RCC warrants further studies.
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